BRD3308,98.07%

产品编号:Bellancom-19618| CAS NO:1550053-02-5| 分子式:C15H14FN3O2| 分子量:287.29

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-19618
1100.00 杭州 北京(现货)
Bellancom-19618
1600.00 杭州 北京(现货)
Bellancom-19618
3000.00 杭州 北京(现货)
Bellancom-19618
5000.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

BRD3308

产品介绍 BRD3308 是一种高选择性的 HDAC3 抑制剂,IC50 为 54 nM。BRD3308 对 HDAC3 的选择性是 HDAC1 (IC50 为 1.26 μM) 或 HDAC2 (IC50 为 1.34 μM) 的 23 倍。BRD3308 抑制由炎性细胞因子或糖脂毒性应激诱导的胰腺 β 细胞凋亡,并增加功能性胰岛素释放。BRD3308 还可激活 HIV-1 转录并破坏 HIV-1 潜伏期。
生物活性

BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency.

体外研究

BRD3308 (5-30 µM; 6-24 hours) treatment increases HIV-1 expression in the 2D10 cell line.
BRD3308 (15 µM; overnight) is able to induce outgrowth of HIV-1 from latently infected cells ex vivo in resting CD4+ T cells. BRD3308 inhibits HDAC1, HDAC2 and HDAC3 with Ki values of 5.1 μM, 6.3 μM and 29 nM, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line: 2D10 cells
Concentration: 5 µM, 10 µM, 15 µM, or 30 µM
Incubation Time: 6 hours, 12 hours, 18 hours, or 24 hours
Result: An increase in HIV-1 expression was observed.
体内研究
(In Vivo)

BRD3308 (5 mg/kg; intraperitoneal injection; every second day; male Zucker Diabetic Fatty rats) treatment reduces hyperglycaemia and increases insulin secretion in a rat model of type 2 diabetes. At the end of the hyperglycaemic clamp, circulating insulin levels are significantly higher in BRD3308-treated rats. Pancreatic insulin staining and contents are also significantly higher. BRD3308 preserves the functional β-cell mass against glucolipotoxicity in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Zucker Diabetic Fatty (Obese) rats (6-week-old)
Dosage: 5 mg/kg
Administration: Intraperitoneal injection; every second day
Result: Reduced hyperglycaemia and increased insulin secretion in a rat model of type 2 diabetes.
体内研究

BRD3308 (5 mg/kg; intraperitoneal injection; every second day; male Zucker Diabetic Fatty rats) treatment reduces hyperglycaemia and increases insulin secretion in a rat model of type 2 diabetes. At the end of the hyperglycaemic clamp, circulating insulin levels are significantly higher in BRD3308-treated rats. Pancreatic insulin staining and contents are also significantly higher. BRD3308 preserves the functional β-cell mass against glucolipotoxicity in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Zucker Diabetic Fatty (Obese) rats (6-week-old)
Dosage: 5 mg/kg
Administration: Intraperitoneal injection; every second day
Result: Reduced hyperglycaemia and increased insulin secretion in a rat model of type 2 diabetes.
体内研究

BRD3308 (5 mg/kg; intraperitoneal injection; every second day; male Zucker Diabetic Fatty rats) treatment reduces hyperglycaemia and increases insulin secretion in a rat model of type 2 diabetes. At the end of the hyperglycaemic clamp, circulating insulin levels are significantly higher in BRD3308-treated rats. Pancreatic insulin staining and contents are also significantly higher. BRD3308 preserves the functional β-cell mass against glucolipotoxicity in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Zucker Diabetic Fatty (Obese) rats (6-week-old)
Dosage: 5 mg/kg
Administration: Intraperitoneal injection; every second day
Result: Reduced hyperglycaemia and increased insulin secretion in a rat model of type 2 diabetes.
性状Solid
溶解性数据
In Vitro: 

DMSO : 250 mg/mL (870.20 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.4808 mL 17.4040 mL 34.8080 mL
5 mM 0.6962 mL 3.4808 mL 6.9616 mL
10 mM 0.3481 mL 1.7404 mL 3.4808 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (7.24 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (7.24 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (7.24 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (7.24 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服